# AbCellera Biologics Inc. Common Shares (ABCL) insider trading

> In the 12 months to Nov 15, 2026, 4 ABCL insiders reported open-market purchases of $3.5M across 11 filings; no open-market sales were filed.

Canonical: https://massive.com/quote/abcl/insider-trading
Latest filing: 2026-11-13 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $0 | 0 filings · 0 insiders |
| Open-market purchases | $3.5M | 11 filings |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Thermopylae Holdings Ltd. | 10% owner | — | $1.4M | 3 | — | 2026-11-12 |
| Michael R. Hayden | Director | — | $1.1M | 2 | — | 2026-08-24 |
| Andrew Booth | Chief Financial Officer | — | $627.0K | 3 | — | 2026-11-13 |
| John S. Montalbano | Director | — | $384.2K | 3 | — | 2026-08-18 |

## Open-market trades by filing

11 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-13 | 2026-11-13 | Andrew Booth | Chief Financial Officer | Purchase | 8,600 | $11.33 | $97.4K | 491,400 | — |
| 2026-11-12 | 2026-11-12 | Thermopylae Holdings Ltd. | 10% owner | Purchase | 60,565 | $11.54 | $698.9K | 56,194,662 | — |
| 2026-08-24 | 2026-08-24 | Michael R. Hayden | Director | Purchase | 53,613 | $10.64 | $570.4K | 1,373,397 | — |
| 2026-08-18 | 2026-08-18 | John S. Montalbano | Director | Purchase | 10,000 | $11.03 | $110.3K | 251,000 | — |
| 2026-08-14 | 2026-08-12 | Michael R. Hayden | Director | Purchase | 46,387 | $10.37 | $481.0K | 1,319,784 | — |
| 2026-08-14 | 2026-08-14 | Andrew Booth | Chief Financial Officer | Purchase | 37,200 | $10.32 | $383.9K | 482,800 | — |
| 2026-05-18 | 2026-05-14 | John S. Montalbano | Director | Purchase | 20,000 | $4.77 | $95.4K | 241,000 | — |
| 2026-03-02 | 2026-02-27 | Thermopylae Holdings Ltd. | 10% owner | Purchase | 38,000 | $3.44 | $130.7K | 56,134,097 | — |
| 2026-02-27 | 2026-02-27 | Andrew Booth | Chief Financial Officer | Purchase | 42,600 | $3.42 | $145.7K | 195,600 | — |
| 2026-02-27 | 2026-02-26 | Thermopylae Holdings Ltd. | 10% owner | Purchase | 177,457 | $3.27 | $580.3K | 56,096,097 | — |
| 2025-11-26 | 2025-11-26 | John S. Montalbano | Director | Purchase | 50,000 | $3.57 | $178.5K | 221,000 | — |

## Other insider activity (not market trades)

- Option exercises: 1 record
- Gifts: 3 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has AbCellera Biologics Inc. Common Shares' CEO sold stock?

No. Carl L. G. Hansen (CEO) made no open-market sales filed as CEO in the last 12 months.

### How current is ABCL’s insider data?

These are ABCL Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The ABCL Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=ABCL&filing_date.gte=2025-11-15&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [AbCellera Biologics Inc. Common Shares (ABCL) stock price](https://massive.com/quote/abcl.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms